Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × Rituximab × Clear all Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Terminated
30 enrolled
A Study Of The Selective PKC-β Inhibitor MS- 553
Phase 1/2 Terminated
60 enrolled 20 charts
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
R/R
Phase 1/2 Terminated
1 enrolled 4 charts
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Phase 1/2 Terminated
43 enrolled 15 charts
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Phase 1 Terminated
249 enrolled 43 charts
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Phase 1 Terminated
98 enrolled
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
Phase 2 Terminated
31 enrolled 10 charts
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Phase 1 Terminated
97 enrolled
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Terminated
1 enrolled 6 charts
Phase 1b Safety and Efficacy Study of TRU-016
Phase 1 Terminated
87 enrolled
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Terminated
84 enrolled 10 charts
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
39 enrolled 10 charts
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
Phase 1 Terminated
35 enrolled
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Phase 1/2 Terminated
2 enrolled 4 charts
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Phase 2 Terminated
18 enrolled 10 charts
BMS-CA180105
Phase 1/2 Terminated
3 enrolled 3 charts
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Phase 2 Terminated
10 enrolled 10 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
Phase 4 Terminated
26 enrolled 13 charts
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Terminated
311 enrolled 12 charts
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Phase 2 Terminated
102 enrolled 8 charts
Bridalveil
Phase 3 Terminated
475 enrolled 9 charts
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
81 enrolled 16 charts
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2 Terminated
2 enrolled 2 charts
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
Phase 4 Terminated
89 enrolled 12 charts
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Phase 2 Terminated
25 enrolled
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 1 Terminated
5 enrolled
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Terminated
12 enrolled 7 charts
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Phase 2 Terminated
10 enrolled 6 charts
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Phase 1 Terminated
9 enrolled
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
5 enrolled
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Terminated
9 enrolled
HYDRIC
Phase 2 Terminated
6 enrolled
Alemtuzumab + Rituximab Consolidation in CLL
Phase 2 Terminated
1 enrolled 2 charts
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Terminated
32 enrolled 7 charts
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Phase 1 Terminated
6 enrolled
Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2 Terminated
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Terminated
18 enrolled
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Phase 1 Terminated
28 enrolled
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Phase 1 Terminated
2 enrolled
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
Phase 2 Terminated
60 enrolled